Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension

Stefano Taddei1, Agostino Virdis, Lorenzo Ghiadoni

  • 1Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. s.taddei@int.med.unipi.it

Insights

Essential hypertension impairs blood vessel dilation due to oxidative stress. Lercanidipine treatment improved vasodilation by restoring nitric oxide (NO) availability and reducing oxidative stress, likely through antioxidant effects.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Oxidative Stress Research

Background:

  • Essential hypertension is linked to reduced endothelium-dependent vasodilation.
  • Oxidative stress contributes to nitric oxide (NO) breakdown in hypertension.
  • Compensatory hyperpolarizing factors may play a role in hypertensive vasodilation dysfunction.

Purpose of the Study:

  • To investigate if calcium antagonist treatment can restore NO availability and prevent hyperpolarization.
  • To assess the antioxidant properties of calcium antagonists in essential hypertension.
  • To evaluate the effects of lercanidipine on endothelium-dependent vasodilation and oxidative stress markers.

Main Methods:

  • Forearm blood flow was measured using strain-gauge plethysmography in healthy controls and hypertensive patients.
  • Intrabrachial infusions of bradykinin, NG-monomethyl-l-arginine (L-NMMA), and ouabain were used to assess vasodilation.
  • The effects of antioxidant vitamin C and 3-month lercanidipine treatment were evaluated.
  • Plasma levels of oxidative stress markers (lipoperoxides, isoprostanes, malondialdehyde) and antioxidant capacity were measured.

Main Results:

  • Hypertensive patients showed blunted bradykinin-induced vasodilation, resistant to L-NMMA but sensitive to ouabain.
  • Vitamin C improved vasodilation in hypertensive patients and restored L-NMMA's inhibitory effect.
  • Lercanidipine treatment reduced oxidative stress markers and improved vasodilation.
  • Lercanidipine restored L-NMMA's inhibitory effect and prevented ouabain's effect, with vitamin C losing its facilitating activity post-treatment.

Conclusions:

  • Lercanidipine enhances endothelium-dependent vasodilation in essential hypertension.
  • The beneficial effects of lercanidipine are attributed to restored NO availability and prevention of hyperpolarization.
  • Antioxidant activity is likely the primary mechanism underlying lercanidipine's therapeutic effects in hypertensive patients.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...